Beyond white blood cell monitoring: Screening in the initial phase of clozapine therapy

Journal of Clinical Psychiatry

Volumn 73, Issue 10, 2012, Pages 1307-1312

  Cohen, Dan ^a,b   Bogers, Jan P A M ^c   Van Dijk, Daniel ^d   Bakker, Bert ^e   Schulte, Peter F J ^f  

^a Mental Health Care Organization North Holland North   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Mental Care Organization Rivierduinen   (Netherlands)

^d Mental Care Organization Friesland   (Netherlands)

^e Parnassia Bavo Castricum ^*  (Netherlands)

^f Mental Health Service North Holland North   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868155778     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11r06977     Document Type: Review

References (41)

1. Idänpään-Heikkilä J, Alhava E, Olkinuora M, et al. Clozapine and agranulocytosis [letter]. Lancet. 1975;2(7935):611.
2. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
3. Committee for Proprietary Medicinal Products (CPMP) summary information on referral opinion following arbitration pursuant to article 30 of council directive 2001/83/EC for Leponex and associated names. European Agency for the Evaluation of Medicinal Products Web site. http://www.ema.europa.eu/docs/en-GB/ document-library/Referrals-document/Leponex-30/WC500010966.pdf. Published November 12, 2002. Accessed July 19, 2012.
4. Clozaril [package insert]. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/019758s054lbl.pdf? utm-campaign=Google2&utm-source=fdaSearch&utm-medium= website&utm-term=clozaril&utm-content=4. Updated November 2004. Accessed June 5, 2012.
5. McEvoy JP, Lieberman JA, Stroup TS, et al CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610. doi:10.176/api.ajp.163.4.60 Pu
6. Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715-723.
7. Leucht S, Corves C, Arbter D, et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
8. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry. 1999;175(6):576-580.
9. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology. 1997;8(6):671-677. Pu
10. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.
11. Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71(3):304-311.
12. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? a critical appraisal of the FIN-11 study. Schizophr Res. 2010;117(1):68-74.
13. Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapineinduced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759-768.
14. Berk M, Fitzsimons J, Lambert T, et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs. 2007;21(2):117-127.
15. Agid O, Foussias G, Singh S, et al. Where to position clozapine: re-examining the evidence. Can J Psychiatry. 2010;55(10):677-684.
16. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-167.
17. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483-488.
18. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(suppl 3):3-7. Pu
19. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(12):2739-2748.
20. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709-1711.
21. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry. 2007;68(4):533-541.
22. Koller EA, Schneider B, Bennett K, et al. Clozapine-associated diabetes Am J Med. 2001;111(9):716-723.
23. Centers for Disease Control and Prevention. Diabetic ketoacidosis as first-listed diagnosis. http://www.cdc.gov/diabetes/statistics/dkafirst/table7. htm. Updated April 20, 2012. Accessed June 6, 2012.
24. Henriksen OM, Røder ME, Prahl JB, et al. Diabetic ketoacidosis in Denmark incidence and mortality estimated from public health registries. Diabetes Res Clin Pract. 2007;76(1):51-56.
25. Meltzer HY, Alphs L, Green AI, et al International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91.
26. De Hert M, Hudyana H, Dockx L, et al. Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry. 2011;26(1): 34-44.
27. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012;38(3):592-598.
28. Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry. 2004;38(11-12):915-922.
29. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354(9193):1841-1845.
30. Novartis Pharmaceuticals Canada. Association of Clozaril (clozapine) with cardiovascular toxicity. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/ prof/-2002/clozaril-hpc-cps-eng.php.Updated February 19, 2009. Accessed June 5, 2012.
31. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007;30(1):47-57.
32. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001;345(3):224-225.
33. Degner D, Bleich S, Grohmann R, et al. Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry. 2000;34(5):880.
34. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol. 1977;11(3):199-201.
35. Barnes TRE, Paton C, Cavanagh M-R, et al UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 2007;33(6): 1397-1403.
36. Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008;69(2):316-322.
37. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166(3): 345-353.
38. Kerwin R. When should clozapine be initiated in schizophrenia? some arguments for and against earlier use of clozapine. CNS Drugs. 2007; 21(4):267-278.
39. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003; 64(1):30-34.
40. Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother. 2008;42(6):852-860.
41. Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third-line status for schizophrenia? a decision-analytic model. J Ment Health Policy Econ. 2004;7(2):77-85.